title: Donor origin CAR T cells: graft versus malignancy effect without GVHD, a systematic review.
abstract: CD19, CD20 chimeric antigen receptor T (CAR T) cell therapy has shown promising results for the treatment of relapsed or refractory hematological malignancies. Best results have been reported in acute lymphoblastic leukemia patients with a complete response rate above 80%. Patients who received donor-derived CAR T cells for the relapsed malignancy after stem cell transplantation (allogenic hematopoietic stem cell transplant) were identified from the published trials. A total of 72 patients from seven studies were treated with donor-derived CAR T cells. Only five out of 72 patients (6.9%) developed graft versus host disease. Use of donor-derived CAR T cell for relapse prophylaxis, minimal residual disease clearance or salvage from relapse is therefore highly effective, and risk of graft versus host disease flare is very low. Side effects include cytokine release syndrome, tumor lysis syndrome, B-cell aplasia along with CNS toxicity.
authors.affiliation: Department of Medicine, Hematology & Oncology, University of Arizona, Tucson, AZ, USA.|Arizona Cancer Center, University of Arizona, Tucson, AZ, USA.
authors.forename: Faiz
authors.initials: F
authors.lastname: Anwer
authors.affiliation: James Paget University Hospital, Norfolk, UK.
authors.forename: Al-Aman
authors.initials: AA
authors.lastname: Shaukat
authors.affiliation: Department of Medicine, University of Arizona, Tucson, AZ, USA.|College of Public Health, University of Arizona, Tucson, AZ, USA.
authors.forename: Umar
authors.initials: U
authors.lastname: Zahid
authors.affiliation: Department of Medicine, University of Arizona, Tucson, AZ, USA.
authors.forename: Muhammad
authors.initials: M
authors.lastname: Husnain
authors.affiliation: College of Pharmacy, University of Arizona, Tucson, AZ, USA.
authors.forename: Ali
authors.initials: A
authors.lastname: McBride
authors.affiliation: Department of Medicine, Hematology & Oncology, University of Arizona, Tucson, AZ, USA.|Arizona Cancer Center, University of Arizona, Tucson, AZ, USA.
authors.forename: Daniel
authors.initials: D
authors.lastname: Persky
authors.affiliation: Arizona Cancer Center, University of Arizona, Tucson, AZ, USA.
authors.forename: Melissa
authors.initials: M
authors.lastname: Lim
authors.affiliation: University of Arizona Zuckerman College of Public Health, Tucson, AZ, USA.
authors.forename: Nida
authors.initials: N
authors.lastname: Hasan
authors.affiliation: Department of Medicine, University of Arizona, Tucson, AZ, USA.
authors.forename: Irbaz Bin
authors.initials: IB
authors.lastname: Riaz
mesh_terms: D000818:Animals; D018941:Antigens, CD19 / Q000276:immunology; D018951:Antigens, CD20 / Q000276:immunology; D006086:Graft vs Host Disease / Q000276:immunology*; D020350:Graft vs Tumor Effect / Q000276:immunology*; D019337:Hematologic Neoplasms / Q000276:immunology / Q000628:therapy*; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D016219:Immunotherapy, Adoptive / Q000379:methods*; D011948:Receptors, Antigen, T-Cell / Q000235:genetics / Q000378:metabolism*; D011993:Recombinant Fusion Proteins / Q000235:genetics; D012008:Recurrence; D013601:T-Lymphocytes / Q000276:immunology* / Q000637:transplantation; D014019:Tissue Donors; D014184:Transplantation, Homologous
chemical_list: D018941:Antigens, CD19; D018951:Antigens, CD20; D011948:Receptors, Antigen, T-Cell; D011993:Recombinant Fusion Proteins
keywords: allogenic stem cell transplantation; chimeric antigen T cells; graft versus leukemia; hematological malignancy; relapse; salvage